Assessment system based on the genotyping of patients allowed to correctly classify 69.2% of patients with severe neutropenia and 75.7% of patients without this adverse effect to the appropriate categories, confirming that the SNPs in ABCC2 and SLCO1B3 genes may be a predictive factor for docetaxel induced neutropenia. This evidence concerns the gene SLCO1B3 and neutropenia.